Literature DB >> 21389694

Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease.

Mehmet Kanbay1, Mahmut Ilker Yilmaz, Alper Sonmez, Faruk Turgut, Mutlu Saglam, Erdinc Cakir, Mujdat Yenicesu, Adrian Covic, Diana Jalal, Richard J Johnson.   

Abstract

BACKGROUND: An elevated serum uric acid level is strongly associated with endothelial dysfunction and inflammation, both of which are common in chronic kidney disease (CKD). We hypothesized that endothelial dysfunction in subjects with CKD would correlate with uric acid levels.
MATERIALS AND METHODS: We evaluated the association between serum uric acid level and ultrasonographic flow-mediated dilatation (FMD) in 263 of 486 patients with recently diagnosed CKD (stage 3-5) (48% male, age 52 ± 12 years). To minimize confounding, 233 patients were excluded because they were diabetic, had established cardiovascular complications or were taking drugs (renin-angiotensin system blockers, statins) interfering with vascular function.
RESULTS: Serum uric acid level was significantly increased in all stages of CKD and strongly correlated with estimated glomerular filtration rate (eGFR-MDRD); FMD was inversely associated with serum uric acid (r = -0.49, p < 0.001). The association of serum uric acid with FMD remained after adjustment for age, gender, smoking, LDL cholesterol, eGFR, high-sensitivity C-reactive protein, systolic blood pressure, proteinuria, and homeostatic model assessment index (β = -0.27, p < 0.001).
CONCLUSION: Increased serum uric acid is an independent predictor of endothelial dysfunction in subjects with CKD.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21389694      PMCID: PMC3064939          DOI: 10.1159/000324847

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  41 in total

1.  Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies.

Authors:  Wolfram Doehner; Nina Schoene; Mathias Rauchhaus; Francisco Leyva-Leon; Darrell V Pavitt; David A Reaveley; Gerhard Schuler; Andrew J S Coats; Stefan D Anker; Rainer Hambrecht
Journal:  Circulation       Date:  2002-06-04       Impact factor: 29.690

2.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

3.  Plasma from ESRD patients inhibits nitric oxide synthase activity in cultured human and bovine endothelial cells.

Authors:  S Xiao; R J Schmidt; C Baylis
Journal:  Acta Physiol Scand       Date:  2000-01

4.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

5.  Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort.

Authors:  Kunitoshi Iseki; Yoshiharu Ikemiya; Taku Inoue; Chiho Iseki; Kozen Kinjo; Shuichi Takishita
Journal:  Am J Kidney Dis       Date:  2004-10       Impact factor: 8.860

6.  Allopurinol improves endothelial dysfunction in chronic heart failure.

Authors:  Colin A J Farquharson; Robert Butler; Alexander Hill; Jill J F Belch; Allan D Struthers
Journal:  Circulation       Date:  2002-07-09       Impact factor: 29.690

7.  A role for uric acid in the progression of renal disease.

Authors:  Duk-Hee Kang; Takahiko Nakagawa; Lili Feng; Susumu Watanabe; Lin Han; Marilda Mazzali; Luan Truong; Raymond Harris; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2002-12       Impact factor: 10.121

8.  Endothelial dilatory function predicts individual susceptibility to renal damage in the 5/6 nephrectomized rat.

Authors:  Simone Gschwend; Hendrik Buikema; Gerjan Navis; Robert H Henning; Dick de Zeeuw; Richard P E van Dokkum
Journal:  J Am Soc Nephrol       Date:  2002-12       Impact factor: 10.121

9.  Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers.

Authors:  Sashi Guthikonda; Christine Sinkey; Therese Barenz; William G Haynes
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

10.  Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk.

Authors:  Giuseppe Mercuro; Cristiana Vitale; Elena Cerquetani; Sandra Zoncu; Martino Deidda; Massimo Fini; Giuseppe M C Rosano
Journal:  Am J Cardiol       Date:  2004-10-01       Impact factor: 2.778

View more
  40 in total

1.  Diagnostic value of quantitative contrast-enhanced ultrasound (CEUS) for early detection of renal hyperperfusion in diabetic kidney disease.

Authors:  Ling Wang; Jian Wu; Jia-Fen Cheng; Xin-Ying Liu; Fang Ma; Le-Hang Guo; Jun-Mei Xu; Tianfu Wu; Chandra Mohan; Ai Peng; Hui-Xiong Xu; Ya-Xiang Song
Journal:  J Nephrol       Date:  2015-02-25       Impact factor: 3.902

Review 2.  Dietary and commercialized fructose: Sweet or sour?

Authors:  Aslihan Yerlikaya; Tuncay Dagel; Christopher King; Masanari Kuwabara; Miguel A Lanaspa; Ana Andres-Hernando; Adrian Covic; Jacek Manitius; Alan A Sag; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2017-02-16       Impact factor: 2.370

3.  Serum calcitonin and endothelial dysfunction in chronic kidney disease: a novel risk factor?

Authors:  Mehmet Kanbay; Mahmut Ilker Yilmaz; Baris Afsar; Mutlu Saglam; Emin Ozgur Akgul; Tuncer Cayci; Kayser Caglar; Hilmi Umut Unal; Mahmut Gok; Abdulgaffar Vural; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2012-03-23       Impact factor: 2.370

Review 4.  The role of uric acid in mineral bone disorders in chronic kidney disease.

Authors:  Baris Afsar; Alan A Sag; Cinar Oztosun; Masanari Kuwabara; Mario Cozzolino; Adrian Covic; Mehmet Kanbay
Journal:  J Nephrol       Date:  2019-04-27       Impact factor: 3.902

5.  Albuminuria, proteinuria, and urinary albumin to protein ratio in chronic kidney disease.

Authors:  Men-Tai Wu; King-Kwan Lam; Wen-Chin Lee; Kao-Tai Hsu; Chien-Hsing Wu; Ben-Chung Cheng; Hwee-Yeong Ng; Po-Jui Chi; Yueh-Ting Lee; Chien-Te Lee
Journal:  J Clin Lab Anal       Date:  2012-02       Impact factor: 2.352

6.  Uric acid level and erectile dysfunction in patients with coronary artery disease.

Authors:  Yalcin Solak; Hakan Akilli; Mehmet Kayrak; Alpay Aribas; Abduzhappar Gaipov; Suleyman Turk; Santos E Perez-Pozo; Adrian Covic; Kim McFann; Richard J Johnson; Mehmet Kanbay
Journal:  J Sex Med       Date:  2013-09-25       Impact factor: 3.802

7.  Vascular Function and Uric Acid-Lowering in Stage 3 CKD.

Authors:  Diana I Jalal; Emily Decker; Loni Perrenoud; Kristen L Nowak; Nina Bispham; Tapan Mehta; Gerard Smits; Zhiying You; Douglas Seals; Michel Chonchol; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2016-09-12       Impact factor: 10.121

8.  The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients.

Authors:  Dilara Bayram; M Tuğrul Sezer; Salih İnal; Atila Altuntaş; Veysel Kıdır; Hikmet Orhan
Journal:  Clin Exp Nephrol       Date:  2014-08-01       Impact factor: 2.801

9.  Impaired arterial responsiveness in untreated gout patients compared with healthy non-gout controls: association with serum urate and C-reactive protein.

Authors:  Svetlana Krasnokutsky; Aaron Garza Romero; Daisy Bang; Virginia C Pike; Binita Shah; Talia F Igel; Irina Dektiarev; Yu Guo; Judy Zhong; Stuart D Katz; Michael H Pillinger
Journal:  Clin Rheumatol       Date:  2018-02-15       Impact factor: 2.980

Review 10.  Obesity-related cardiorenal disease: the benefits of bariatric surgery.

Authors:  Wiebke Fenske; Thanos Athanasiou; Leanne Harling; Christiane Drechsler; Ara Darzi; Hutan Ashrafian
Journal:  Nat Rev Nephrol       Date:  2013-08-06       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.